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Abstract
Background: Improving prediction of treatment outcomes in chronic hepatitis C (CHC) genotype 4 (G4) is
necessary to increase sustained viral response (SVR) rates. Vitamin D related and interferon stimulated genes are
good candidates as they are recently crosstalk altering interferon response. Thus single nucleotide polymorphisms
(SNPs) within some of these genes and multiple stepwise regression analysis including other independent
predictors (IL28B(rs12979860), serum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of
200 Egyptian CHC patients treated with Pegylated interferon-alpha (Peg-IFN) plus ribavirin.
Methods: SNPs in cytochrome P-450 (CYP2R1)(rs10741657AG), vitamin D receptor (VDR)(rs2228570AG,
rs1544410CT), oligoadenylate synthetases-like (OASL)(rs1169279CT) and adenosine deaminases acting on RNA
(ADAR)(rs1127309TC) genes were analyzed by real-time PCR.
Results: The carrier state of A allele in VDR rs2228570 and CYP2R1 rs10741657 genes were independently
associated with SVR [OR 6.453 & 3.536, p < 0.01 respectively]. Combining carriers of A allele in CYP2R1 and VDR
genes with IL28B C/C genotype increased the probability of SVR from 80 % to reach 87.8 %, 93 % and 100 %. No
relation was found between VDR rs1544410CT, ADAR rs1127309TC, OASL rs1169279CT polymorphisms and
treatment outcome. Combining VDR rs2228570 A/A genotype with IL28B C/C genotype increased the probability of
SVR from 82 % to reach 100 % and from 29 % to reach 80 % in C/T+ T/T IL28B genotype in none F4 liver disease
patients.
Conclusion: Vitamin D related (VDR rs2228570 and CYP2R1 rs10741657) and IL28B rs12979860 genes
polymorphisms accurately assure SVR in naïve CHC G4 patients treated with low cost standard therapy.
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Background
Hepatitis C virus (HCV) is a hepatotropic non-
cytopathic positive strand RNA virus, which repre-
sents a major cause of chronic hepatitis, cirrhosis,
and hepatocellular carcinoma, affecting over 150 mil-
lion people worldwide. In Egypt the condition is even
worse just about every family is touched by hepatitis
C it kills an estimated 40,000 Egyptian per year where
at least 1 in every 10 of the population aged 15 to 59
is infected [1].
Pegylated interferon-alpha (Peg-IFN) plus ribavirin
(RBV) constitutes the standard cornerstone therapy
for chronic hepatitis C (CHC). Even though less than
half of the patients are able to achieve sustained viral
response (SVR) while the rest don’t show response or
experience sever complications [2]. By the introduc-
tion of the novel direct acting antivirals (DAAs),
CHC treatment modalities dramatically evolve in-
creasing rates of SVR, treatment efficacy and toler-
ability especially in patients with advanced liver
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disease (fibrosis METAVIR score F3 or F4) [3, 4]. Yet,
they are much more expensive if compared to the
standard dual therapy [5] and a more questionable
issue emerged about its availability in treating all
CHC patients especially in low income developing
countries [6]. Recently, according to the latest guide-
lines of the European Association for the Study of the
Liver (EASL) six treatment options are available for
patients infected with HCV genotype 4 (G4), includ-
ing two interferon-containing regimens which are
sofosbuvir and simeprevir and four interferon-free
regimens which are combinations of sofosbuvir and
simeprevir or sofosbuvir and ledipasvir or ombitasvir,
paritaprevir and ritonavir or sofosbuvir and daily
daclatasvir [4]. But EASL declared that the combin-
ation of PegIFN and RBV remains acceptable in set-
tings where none of these options are available [4].
Thus, despite progress in DAAs there is still room
for optimizing the efficacy of the lower cost standard
dual therapy in naïve CHC patients. This aim could
be obtained by further refining the treatment factors
associated with maximal outcome benefits from dual
therapy [7].
Several predictors of successful treatment response of
CHC are identified [8]. Some of these depend on the
virus itself others are host-related, either genetic (inter-
leukin 28B (IL28B) rs12979860 gene polymorphism, gen-
der and race) or acquired (insulin resistance, obesity,
liver steatosis and liver fibrosis stage) [9, 10]. To refine
the predictive capacity of these biomarkers for the re-
sponse to Peg-IFN and RBV, additional baseline predic-
tors of clinical response would be welcomed [10].
Vitamin D appears to possess an important
immune-modulator effect beside its classical action on
calcium metabolism [11]. Deficiency of vitamin D is
very common in CHC patients [12]. Though, conflict-
ing results were found by relating these deficiencies
with the success of Peg-IFN and RBV therapy [13,
14]. Vitamin D undergoes two activation processes
before its interaction with vitamin D receptor (VDR)
[15]. The first activation is performed in the liver by
cytochrome P-450 family 2, subfamily R, polypeptide
1 (CYP2R1) and produces 25-hydroxylated form of
vitamin D [13]. This step produces the main circulat-
ing vitamin D form in serum. By means of CYP27B1,
vitamin D is subjected to its second hydroxylation
which leads to the production of 1,25(OH) active
vitamin D form which interacts with its specific
transmembrane receptor VDR to exert its physio-
logical functions [16]. CYP2R1 and VDR genes have
different polymorphic forms which are recently sug-
gested to influence the efficacy of antiviral therapy.
On the other hand single functional nucleotide poly-
morphism (SNP) of CYP27B1 gene fails to predict
antiviral response in CHC patients mainly genotype 1
[7, 10].
A more recent study found that VDR crosstalk the
Jak–STAT pathway through altered expression of
interferon stimulated genes (ISGs) which results in
calcitriol-mediated increase of hepatocellular response
to interferon-alpha (IFN-α) [17]. Where, signaling the
expression of ISGs by the administration of exogen-
ous interferon provides antiviral action against HCV
through interferon receptors and through Jak–STAT
pathway [18]. Of these ISGs functional SNPs at oli-
goadenylate synthetases-like (OASL) gene and adeno-
sine deaminases acting on RNA (ADAR) gene were
found to affect the response to antiviral therapy of
HCV genotype 1 [19, 20].
Knowing that different HCV genotypes respond differ-
ently to interferon antiviral therapy [21] and based on
the aformetioned information we aimed to investigate
for the first time the influence of SNPs in CYP2R1 gene,
VDR gene, OASL gene and ADAR gene as well as IL28B
gene, serum 25-OH vitamin D levels, serum levels of
AFP and insulin resistance in treatment outcomes of




Two hundred Egyptian patient infected with HCV G4
were enrolled in this study. Baseline and clinical charac-
teristics are summarized in Table 1. The population
study included all patients with CHC G4 attended to Dr.
Yassin Abdel Ghaffar center for liver diseases and re-
searches, Cairo, Egypt who were scheduled to receive
Peg-IFN and RBV therapy in accordance with the
current guidelines [22]. They received Peg-IFN (Pegasys,
Roche Corporation, Kenilworth, NJ or Pegintron, Roche,
Basel, Switzerland) at a dosage of 180 μg per week and
RBV (Copegus, Roche or Rebetol, Schering-Plough,
Puerto Rico, U.S.A.) which was administered according
to body weight (1000 mg/d for patients weighing <75 kg,
1200 mg/d for those weighting ≥75 kg). Patients were se-
lected according to the following criteria: (1) older than
18 years, (2) lack of co-infection with HBV, HIV, EBV,
and CMV, (3) no history of alcohol consumption, (4) no
bilharzias or diabetes mellitus, (5) not suffering from
other autoimmune or hematological diseases and (6)
adherence to treatment. Patients were asked to stick to
the follow-up visits scheduled at week 4, 12, 24, 36, 48,
72 and 6 months after end of the treatment date. Pa-
tients were defined as having a SVR if they had un-
detectable serum HCV-RNA (Roche Amplicor™ Assay)
levels 6 months after the discontinuation of treatment.
All other patients were defined as non-responders
(NRs). The study was approved by the Committee on
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Table 1 Baseline clinical characteristics of HCV-infected patients included in the present study
Characteristics SVR NR P
value
Statistics (univariate)
(n = 91 (n = 109) OR(95%CI)




BMI, median (range), kg/m2 23 ± 12 24 ± 13.5 -
No of injections, median (range) 48(24) 48(67) 0.001 1.035(1.013-1.058)
Tolerability, [n(%)] 91(100) 88(80.7) -
*Adjusted No of injections ,mean ± SEM 39.23 ± 1.179 38.218 ± 1.072 -
Viral load median, IU/mL 460,000 760,580 0.025 0.637(0.429-0.945)
400,000 IU/mL[n(%)] > Viral load 41(45.1) 38(34.9) -
Viral load ≥400,000 IU/mL[n(%)] 50(54.9) 71(65.1) -
aAST median (range), μkat/L 1.66(4.65) 1.44(4.22) -
bALT median (range), μkat/L 2.04(6.22) 1.7(5.63) -
Albumin median (range), g/L 39 ± 20 39 ± 22 -
Bilirubin median (range), μmol/L 13.68 ± 50.45 15.39 ± 44.46 -
Hemoglobin median (range), g/dL 13 ± 6.1 13.5 ± 7 -
Platelets median (range), 109/L 190(241) 160(320) 0.012 3.299(1.306-8.334)
cTLC median (range), 109/μL 6(10) 6.4(6) -
Cholesterol mean ± SD, mmol/L 4.41 ± 0.78 4.69 ± 0.66 -
Glucose median (range), mmol/L 5.27 ± 3.38 5.5 ± 3.1 -
Insulin median (range), pmol/L 79.8 ± 127 62.5 ± 147.2 -
dHOMA-IR median (range) 2.4 ± 5.71 2.2 ± 6.8 -
eAFP median (range), ng/mL 3.3(29.5) 7(29) <0.001 0.165(0.071-0.383)
25-OH Vitamin D median (range),ng/mL 28 ± 38 19 ± 38 <0.001 4.877(2.512-9.468)
Cirrhosis, [n(%)] 5(5.5) 15(13.7) -
Fibrosis stage, [n(%)]
F1 21(42) 12(18.4) 0.006 3.198(1.378-7.419)
F2 16(32) 29(44.6) -
F3 12(24) 16(24.6) -
F4 1(2) 8(12.3) -
Necroinflammatory grade, [n(%)]
A1 26(52) 27(41.5) -
A2 22(44) 27(41.5) -
A3 2(4) 11(17) 0.04 0.204(0.043-0.97)
IL28B rs12979860 [n(%)] Chi2 = 55.2 p < 0.001
C/C 56(61.5) 14(12.8) <0.001 10.857(5.379-21.913)
C/T 31(34.1) 67(61.5) <0.001 0.324(0.181-0.579)
T/T 4(4.4) 28(25.7) <0.001 0.133(0.045-0.395)
T allele carriers/ T allele non carriers 35/56 94/14 <0.001 0.092(0.046-0.186)
a AST, aspartate aminotransferase; b ALT, alanine aminotransferase; c TLC, total leukocyte count; d HOMA-IR, homeostatic model of insulin resistance; e AFP, alfa
feto protein; NR, non-responders; SVR, sustained virological responders; N, number of samples; OR, odds ratio; 95%CI Confidence Interval.; Chi-square test for
genotype distribution; IL28B: interleukin 28 B
*Calculated by general linear model with adjustment for tolerability
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Medical Ethics of ASUH, and informed consent was ob-
tained from each patient for participation and publishing
results obtained. The study was carried out in accord-
ance with the regulations and recommendations of the
Declaration of Helsinki. Blood samples for biochemical,
virologic and genetic studies were obtained during the
month previous to the onset of therapy. Histopatho-
logical data were collected when a liver biopsy per-
formed within the previous six months was available.
Liver biopsy specimens were scored using the METAVIR
system [23]. All biopsies were evaluated and scored by
the same pathologist.
Laboratory analyses
Routine hematological and biochemical tests were per-
formed after an overnight fast with the standard
methods at the center’s laboratory. It includes complete
blood count (CBC), serum transaminases (ALT, AST),
total and conjugated bilirubin, serum albumin, alpha-
feto protein (AFP), blood sugar and serum cholesterol.
Virological testing
For all 200 patient, a baseline serum sample, collected
before starting antiviral therapy, was separated and
stored at _80 °C until used. The presence or absence of
HCV antibodies was detemined by third generation
ELISA (Dia Sorin). Serum HCV RNA was detected by
using the real time polymerase chain reaction (RT-PCR)
(TaqMan Roche Amplicor™ Assay) [24]. Viral load was
classified as low (<400.000 IU/ml) or high (≥400.000 IU/
ml), according to Wittho¨ft et al. [25].
Genotyping
Genomic DNA was extracted with QIAamp DNA Mini
Kit protocol (QIAGEN, Santa Clarita, CA) according to
the manufacturer’s instructions. DNA samples were sub-
jected to DNA quantitation and purity assessment using
the NanoDrop® (ND)-1000 spectrophotometer (Nano-
Drop Technologies, Inc. Wilmington, USA).
Analyses of interleukin 28B gene
Genotyping was carried out by the use of TaqMan®
QRT-PCR Reagents constitutes a ready-to-use system
for the detection of IL-28B rs12979860 polymorphism
using (Assays-by-Design supplied by Applied Biosystems
International ABI; Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions.
Analyses of Vitamin D-related genes
Genotyping was carried out by the use of TaqMan
probes designed to detect the following SNPs: CYP2R1,
rs10741657; VDR, rs2228570; VDR, rs1544410 (custom
TaqMan SNP assay C___2958430_10; C__12060045_20
and C___8716062_10 respectively using Assays-by-
Design supplied by Applied Biosystems International
ABI; Applied Biosystems, Foster City, CA). The SNPs
were selected on the basis of allele frequencies and func-
tional clinical implications [7, 10]. The only nonsynon-
ymous SNP confirmed for the VDR gene was included
in the study. No other nonsynonymous SNPs have been
described to occur in Caucasian individuals with minor
allele frequencies over 0.001.
Analysis of interferon stimulated genes
Genotyping was carried out by the use of TaqMan
probes designed to detect the following SNPs: OASL
rs1169279 and ADAR, rs1127309 (custom TaqMan SNP
assay C___1263582_10 and C____131814_1_; using
Assays-by-Design supplied by Applied Biosystems Inter-
national ABI; Applied Biosystems, Foster City, CA). The
SNPs were also selected on the basis of allele frequencies
and functional of clinical implications [19, 20] (see the
website http://www.ncbi.nlm.nih.gov/projects/SNP/).
Putative departures of Hardy-Weinberg Equilibrium
was calculated by using the software Haploview 4.1. [26].
Serum 25-OH vitamin D and serum insulin
Serum human 25-OH vitamin D levels were determined
by enzyme linked immunosorbent assay (ELISA) using
commercially available kits (DRG International, Inc.,
USA). The data are expressed as nanograms per milli-
liter. Serum insulin was also quantified using ELISA
technique using commercial available kit (Nova Tec
Immundiagnostica GmbH, Germany). The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated from fasting insulin and FBG by the following
equation: HOMA-IR = fasting insulin (μU/mL) × FBG
(mg/dL)/405 [27]. All ELISA procedures were done by
Hyprep Automated ELISA system (Hyperion Inc, Miami,
FL) according to the manufacturer’s instructions.
Statistical analysis
IBM SPSS statistics (V. 22.0, IBM Corp., USA, 2013)
was used for data analysis. Shapiro-Wilk test was used
to test the normal distribution of data. Continuous vari-
ables were expressed as mean ± SD for parametric data
while median (range) was used for non- parametric data.
Additionally, categorical variables were presented as fre-
quencies (percentage). Comparison between two inde-
pendent mean groups for parametric data were
performed using Student’s t-test and Wilcoxon rank-
sum test was carried out for comparison between two
independent groups for non-parametric. The associa-
tions between categorical variables were evaluated using
a Pearson chi-squared test and, when appropriate, a chi-
squared test for linear trend. Hardy–Weinberg equilib-
rium was assessed in the study population. General lin-
ear model was used to control for potential confounders.
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Significant covariates at binary logistic regression ana-
lysis were included in a multivariate stepwise logistic re-
gression model with a forward approach to identify
independent predictors of SVR. In addition, any skewed
data were logarithmically transformed before performing
simple and multiple binary stepwise regression analyses.
The AUROC indicated the prediction capacity of this
analysis. The results were reported as odds ratio (OR)
and their 95 % confidence intervals (CIs). A difference of
p <0.05 was considered significant.
Results
The clinical and demographic characteristics of the 200
patient are shown in Table 1. 54.5 % of the patients (n =
109) were classified as NR and 45.5 % (n = 91) were clas-
sified as SVR. The univariate analysis expressed in Table
1 revealed the following variables were significantly
linked with SVR rates: lower viral load (OR = 0.637–
95 % CI =0.429–0.945- p = 0.025), higher platelets count
(OR = 3.299–95 % CI =1.306–8.334- p = 0.012), lower
serum AFP levels (OR = 0.165–95 % CI =0.071–0.383- p
< 0.001), higher serum 25-OH vitamin D levels (OR =
4.877–95 % CI =2.512–9.468- p < 0.001), the absence of
higher fibrosis grade (OR = 3.198–95 % CI =1.378–
7.419- p = 0.006), and the absence of A3 necroinflamma-
tory grade (OR = 0.204–95 % CI =0.043–0.97- p = 0.04).
Additionally, number of injections was found to be re-
lated to SVR with (OR = 1.035–95 % CI =1.013–1.058-
p = 0.001). General linear model was performed to con-
trol confounding variables as (age, gender, BMI and
interferon tolerability) and found that all adjusted values
for variables were still significantly related to treatment
response except for the adjusted number of injections
which loses its significance to SVR due to the effect of
interferon tolerability where number of injections were
found to be heavily dependent on tolerability with p <
0.001 rather than on treatment response with p = 0.204.
Exploring the association of IL28B rs12979870,
CYP2R1 rs10741657, VDR (rs2228570, rs1544410),
OASL rs1169279 and ADAR rs1127309 genes poly-
morphism with response to antiviral treatment were
shown in Tables 1 and 2, it was found that the absence
of IL28B rs12979870T allele carrier state (chi2 = 51.69- p
< 0.001), the prescence of CYP2R1 rs10741657 and VDR
rs2228570 A allele carrier states (chi2 = 4.888- p = 0.027,
chi2 = 4.138- p = 0.042 respectively), and OASL
rs1169279T allele carrier state (chi2 = 6.23- p = 0.013),
were significantly predicting SVR in CHC G4 patients.
These significant variables were included in the multi-
variate binary logistics regression analysis after controlling
for the confounders. Where, IL28B gene polymorphism
showed the highest significance as C/T + T/T genotypes
were inversely associated with SVR (OR = 0.064–95 % CI
=0.022–0.184- p < 0.001). Beside serum AFP levels and
basic viral load were found to be inversely related to SVR
(OR = 0.241–95 % CI =0.071–0.816- p = 0.022) and (OR =
0.523–95 % CI =0.228–0.951- p = 0.033), respectively. On
the other hand, serum 25-OH vitamin D levels were con-
firmed by this study to predict SVR (OR = 7.361–95 % CI
=2.828–19.162- p < 0.001). A negative cut-off value for
serum 25-OH vitamin D levels was calculated to be up to
12 ng/ml with a negative predictive value of 87.5 % and
sensitivity of 95.6 %. While a positive predictive value of
69.6 % and specificity of 93.6 % was calculated for the
positive cut-off value to be up to 38 ng/ml.
Additionally, the carrier state of allele A at CYP2R1
rs10741657 was found to be inversely related to the
probability of therapeutic failure (OR = 3.536–95 % CI =
1.444–8.659- p = 0.006). Besides, the carrier state of the
minor A allele at VDR rs2228570 was significantly re-
lated to the probability of obtaining SVR (OR = 6.453–
95 % CI =2.348–17.739- p < 0.001).
The ROC was plotted in accordance with the same
model as expressed in Fig. 1. The predictive capacity of
the final model was quite good as indicated by the
AUROC 0.887(95 % CI = 0.842–0.993). Multiple stepwise
logistic regression analysis was made to establish the in-
crease in the predictive value of the well-known and rec-
ognized IL28B rs12979870 C/T polymorphism. It
showed that our model presented significantly increase
the sensitivity of IL28B rs12979870 from 61.5 % to reach
75.8 % as well as increasing the accuracy of IL28B
rs12979870 from 75.5 % to reach 81 % without signifi-
cantly affecting IL28B rs12979870 specificity to be
85.3 %.
For confirming the integrative role of VDR
rs2228570, CYP2R1 rs10741657 polymorphisms with
IL28B rs12979870 polymorphism we further classified
our SVR data into four groups depending on IL28B
genotype regarding the carrier state of both CYP2R1
rs10741657 and VDR rs2228570 gene. Based on our
results the rate of SVR was predicted by 80 % of
IL28B C/C genotype patients. We confirmed for the
first time that the combination of A allele carrier of
VDR rs2228570 gene with IL28B C/C genotype in-
creases SVR rate to reach 93 % and 87.8 % for A al-
lele carrier of CYP2R1 rs10741657 gene with IL28B
C/C (P < 0.001). Additionally, for each examined vari-
able it was found that there is a highly significant lin-
ear trend in the decrease of the SVR rate as shown
in Table 3. Formulating a model combining A allele
carrier of VDR rs2228570 and CYP2R1 rs10741657
gene and IL28B C/C genotype increased the SVR rate
reaching 100 % and 17 % in non A allele carrier of
VDR rs2228570 and CYP2R1 rs10741657 gene with
IL28B C/T + T/T genotype (P < 0.001).
Interestingly we investigate the role of our predic-
tors in different fibrosis grade models. Actually liver
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biopsies were available for 115 patient. So 106 patient
remained after excluding advanced fibrosis F4 and
cirrhotic patient at which 53.4 % (n = 57) were NR
and 46.2 % (n = 49) were SVR as shown in Table 4.
Univariate analysis showed that some variables
significantly predict SVR as: higher serum 25-OH
vitamin D levels (OR = 1.068–95 % CI =1.024–1.115-
p = 0.002), the absence of IL28B rs12979870T allele
carrier state (chi2 = 26.281- p < 0.001) and the
presence of VDR rs2228570 A/A genotype state (chi2
= 8.511- p = 0.018). CYP2R1 rs10741657 A allele
carrier state showed insignificant relation to SVR
(chi2 = 2.834- p = 0.12). Number of injections was
found to be related to SVR (OR = 1.042–95 % CI
=1.013–1.072 - p = 0.004) and lower serum AFP levels
(OR = 0.563–95 % CI =0.342–0.928- p = 0.024) yet the
adjusted number of injections for interferon tolerabil-
ity and the adjusted serum AFP levels also lost their
significance to SVR with p = 0.386 and p = 0.205
respectively.
Multivariate binary logistic regression analysis were
made after controlling for the confounders and found
that IL28B gene polymorphism showed highest signifi-
cance as C/T + T/T genotypes were inversely associ-
ated with SVR (OR = 0.138–95 % CI =0.045–0.423- p
= 0.001). While, serum 25-OH vitamin D levels (OR =
1.076–95 % CI =1.013–1.144- p = 0.018) and also the
presence of A/A genotype state of VDR rs2228570
(OR = 10.3–95 % CI =1.118–94.887- p = 0.04) were
directly associated with SVR. The ROC was plotted in
accordance with the same model showed that the
AUROC was 0.837 (95 % CI = 0.76–0.951). Multiple
stepwise logistic regression analysis showed that our
model significantly increase the sensitivity of IL28B
rs12979870 from 57.1 % to reach 67.3 % as well as
increasing the accuracy of IL28B rs12979870 from
Table 2 Association analysis of genes polymorphisms with the response to antiviral treatment
Genotype/ Allele SVR NR P
value
OR(95%CI)
N = 91 N = 109
CYP2R1 rs10741657 [n(%)] Chi2 = 5.38 p = 0.06
A/A 7(7.7) 4(3.7)
A/G 44(48.4) 40(36.7)
G/G 40(44) 59.6))65 0.028 0.531(0.302-0.933)
A allele carriers/A allele non carriers 51/40 44/65 0.027 1.884(1.072-3.310)
VDR rs2228570 [n(%)] Chi2 = 8.66 p = 0.013
A/A 13(14.3) 4(3.7) 0.013 4.375(1.374-13.932)
A/G 36(39.6) 39(35.8)
G/G 42(46.2) 66(60.6)
A allele carriers/A allele non carriers 49/42 43/66 0.042 1.791(1.019-3.146)




T allele carriers/ T allele non carriers 61/30 71/38
OASL rs1169279 [n(%)] Chi2 = 5.4 p = 0.06
C/C 19(20.9) 39(55.8) 0.022 0.474(0.250-0.898)
C/T 52(57.1) 49(45)
T/T 20(22) 21(19.3)
T allele carriers/ T allele non carriers 72/19 70/39 0.013 2.26(1.182-4.318)




T allele carriers/ T allele non carriers 61/30 71/109
OR, odds ratio; 95%CI Confidence Interval; n.s., non-significant; SVR: sustained viral response; NR: non response; CYP2R1: cytochrome P-450 family 2, subfamily R;
VDR: vitamin D receptor; OASL: oligoadenylate synthetases-like; ADAR: adenosine deaminases acting on RNA
Chi-square test for genotype distribution
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74.5 % to reach 77.4 % without significantly affecting
IL28B rs12979870 specificity to be 89.5 %.
Classifying our SVR data into four groups depending
on IL28B genotype found that combining IL28B C/C
genotype with VDR rs2228570 A/A genotype increased
the predictive capacity of IL28B C/C genotype from
82.2 % to reach 100 %. More importantly combining
VDR rs2228570 A/A genotype with IL28B C/T + T/T in-
creased the SVR from 29 % to reach 80 %.
By formulating a second model excluding F3, F4 and
cirrhotic patients 78 patient remained at which 52.5 %
(n = 41) were NR and 47.4 % (n = 37) were SVR. It was
found that IL28B C/C genotype is the only predictor of
SVR (OR = 20.81–95 % CI =5.394–80.286 - p < 0.001).
The AUROC equals 0.774 (95 % CI = 0.665–0.883) the
calculated specificity, sensitivity and accuracy were
92.7 %, 62.2 % and 78.2 % respectively.
Discussion
The need for optimizing the standard dual anti-HCV
therapy is mandatory owing to the high socioeconomic
burden associated with recently introduced DAAs [6, 28].
Although DAAs showed strong anti-HCV effects, DAA
monotherapy induced drug-resistant and virus mutations.
Concluding that the main role of DAAs has been to in-
















Fig. 1 ROC curve of the multivariate analysis. Area under the curve (AUC) was 0.887 (95 % CI = 0.842–0.993)
Table 3 Rates of SVR in relationship to IL28B rs12979860 and vitamin D related genes polymorphisms
SVR P value
IL28B rs12979860 C/C C/C C/T + T/T C/T + T/T
CYP2R1 rs10741657 A allele carrier Non A carrier A allele carrier Non A carrier
N(%) 29/33 (87.8 %) 27/37(72.9 %) 22/62(35.4 %) 13/68(19.1 %) <0.001
VDR rs2228570 A allele carrier Non A carrier A allele carrier Non A carrier
N(%) 27/29(93 %) 29/41(70.7 %) 23/66(34.8 %) 12/64(18.7) <0.001
CYP2R1 & VDR A allele carrier Non A carrier A allele carrier Non A carrier
N(%) 17(100 %) 15/23(65.2 %) 15/30(50 %) 6/35(17 %) <0.001
The statistical analysis was performed using a chi-squared test for linear trend
IL28B: Interleukin 28 B; SVR: sustained viral response; CYP2R1: cytochrome P-450 family 2, subfamily R; VDR: vitamin D receptor
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This paves the way for elucidating new markers that
would improve the prediction of Peg-IFN and RBV treat-
ment outcomes. Although several studies have identified
specific viral and host genetic factors that predict treat-
ment outcomes, studies regarding G4 are few and the pur-
suit of further surrogate factors able to optimize
therapeutic regimes remains challenging [30]. Due to
these facts, we have a great research interest in examining
for the first time the relationship between previously
described polymorphisms of vitamin D related genes and
ISGs with the treatment of HCV G4 patients.
In this study we found a predictive potential of base-
line 25-OH vitamin D levels on treatment outcomes. Re-
cent findings from various studies investigating the
predictive role of vitamin D levels offered conflicting
evidences. On one hand low pretreatment vitamin D
concentrations correlated with poor responsiveness to
antiviral therapy [31] and on the other hand Kitson et al.,
Table 4 Baseline clinical characteristics of HCV-infected F1, F2 and F3 patients
Characteristics SVR NR P
value
Statistics (univariate)
(n = 49) (n = 57) OR(95%CI)




BMI, median (range), kg/m2 23 ± 12 23 ± 12 -
No of injection,s median (range) 48(24) 24(62) 0.004 1.042 (1.013- 1.072)
Tolerability, [n(%)] 49(100) 43(75.4)
*Adjusted No of injections ,mean ± SEM 37.28 ± 1.74 35.14 ± 1.63 -
Viral load median, IU/mL 432,210 738,902 -
aAST median (range), μkat/L 1.66(4.23) 1.28(4.2) -
bALT median (range), μkat/L 1.78(5.47) 2.091(5.62) -
Albumin median (range), g/L 39 ± 20 39 ± 10 -
Bilirubin median (range), μmol/L 15.39 ± 50.44 13.6 ± 25.6 -
Hemoglobin median (range), g/dL 13 ± 5.6 13.8 ± 4.6 -
Platelets median (range), 109/L 163(236) 170(207) -
cTLC mean ± SD, 109/μL 6.5(1.7) 6.5(1.3) -
Cholesterol mean ± SD, mmol/L 4.1 ± 0.86 4.2 ± 0.6 -
Glucose median (range), mmol/L 5.27 ± 3.277 5.5 ± 3.1 -
Insulin median (range), pmol/L 79.6 ± 113.2 63.5 ± 133.3 -
dHOMA-IR median (range) 2.5 ± 5.71 2.16 ± 6.04 -
eAFP median (range), ng/mL 3.5(29.5) 8(26.3) 0.024 0.563 (0.342- 0.928)
*Adjusted AFP, mean ± SE 3.5 ± 0.049 3.448 ± 0.045
25-OH Vitamin D mean ± SD, ng/mL 27.3 ± 9.2 21.07 ± 10.1 0.002 1.068(1.024-1.115)
IL28B rs12979860 [n(%)] Chi2 = 31.35 p < 0.001
C/C 28(57.1) 6(10.5) <0.001 11.33(4.09-39.35)
C/T 20(40.8) 35(62.4)
T/T 1(2) 16(28.07)
T allele carriers/ T allele non carriers 21/28 51/6 <0.001 0.088(0.032-0.244)
VDR rs2228570 [n(%)] Chi2 = 8.554 p = 0.014
A/A 9(18.3) 1(1.7) 0.018 12.6(1.53-103.4)
A/G 18(36.7) 24(42.1)
G/G 22(44.8) 32(56.1)
a AST, aspartate aminotransferase; b ALT, alanine aminotransferase; c TLC, total leukocyte count; d HOMA-IR, homeostatic model of insulin resistance; e AFP, alfa
feto protein; NR, non-responders; SVR, sustained virological responders; N, number of samples; OR, odds ratio; 95%CI Confidence Interval.; Chi-square test for
genotype distribution; IL28B: interleukin 28 B
*Calculated by general linear model with adjustment for tolerability
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showed that vitamin D levels seemed unable to predict
treatment response in patients infected with HCV geno-
type 1 [14]. Yet all these hitherto existing analyses were
made on genotype 1 with incomplete consideration of
genetic factors affecting vitamin D levels. In this present
study only G4 was included and the effect of SNP’s within
major regulatory enzyme and in vitamin D receptor, which
were previously shown to affect vitamin D concentrations,
activity and were associated with outcomes of antiviral
therapy, were considered [7, 10, 32].
Our results revealed that high serum 25-OH vitamin
D levels in the multivariate analysis that included the
most potent predictors of viral response at baseline in-
crease the SVR of Peg-IFN and RBV treatment. Also our
study concluded that the negative predictive value was
12 ng/ml for 87.5 % of CHC G4 patients who fails to
reach SVR and the positive predictive value of 69.6 %
was found to be 38 ng/ml which weren’t calculated for
the Egyptian G4 patients before yet found in agreement
to other studies [33]. Interestingly high serum 25-OH
vitamin D levels predicted SVR in noneF4 fibrosis grade
patients which was recently emphasized by previous
studies showing that vitamin D deficiency is associated
with advanced liver disease and is an indicator for a poor
outcome [34, 35]. This highlights the importance of vita-
min D in disease worsening via fibrosis progression and
thus it reflects indirectly the importance of fibrosis reso-
lution in CHC treatment [36].
Additionally, the analysis of an already identified SNP
(rs10741657) within the CYP2R1 gene on chromosome
11p15, which is one of the main polymorphisms found
to be associated with 25(OH) vitamin D circulating
levels [37], showed that the carrier state of allele A at
CYP2R1 gene predicts SVR. This comes in accordance
with a recent study that focused on the association of
the absence of A allele with vitamin D insufficiency [38].
Where, our study confirmed that the presence of A allele
is associated with higher vitamin D serum levels and is
independently predicting SVR in multivariate logistic re-
gression analysis yet it failed to predict response in
noneF4 liver disease patients this might be attributed to
small sample size.
Moreover, studying the common nonsynonymous
SNP in the VDR gene (rs2228570) which cause a
threonine-metionine change in the VDR, found that
those patients carrying the minor A allele in homo-
or heterozygosis obtained SVR at a higher rate than
patients with the rs2228570 G/G genotype. This
agrees with a recent study made on genotype 1 [10].
Our study additionally showed for the first time that
VDR rs2228570 A/A genotype is an independent pre-
dictor of SVR in noneF4 fibrosis grade CHC G4 pa-
tients which adds to the importance of this rs2228570
in predicting treatment success. In contrast we found
no association between SNP in VDR gene (rs1544410)
and treatment outcome in our population. This can
be explained as our study include only single
rs1544410 alone unlike others [10, 39] who categorize
the patients as non-carriers/carriers of the
rs1544410C- rs7975232C - rs731236A three allelic
combination. Thereby, we concluded that we can’t ac-
count on VDR gene rs1544410 SNP alone in predict-
ing therapeutic failure.
Moreover, a recent study highlighting the possible
interaction between VDR and ISGs suggested a role for
vitamin D in the response to IFN-α–based therapy [17].
Importantly, and in line with these observations, our
study assayed two functional SNPs at two important
ISGs which were proven by previous studies to predict
antiviral response of CHC genotype 1 [19, 20]. First one
was OASL being recognized as a significant molecule in
antiviral response with the 2′-5′ oligoadenylate catalytic
activity in innate viral clearance. The SNP (rs1169279) is
located in the 5′ upstream region of the gene and found
to be a promoter polymorphism which may regulate
gene expression. Our findings identified that OASL gene
polymorphism is not the main player in HCV G4 treat-
ment response as T allele carriers lost their significance
in multivariate regression analysis. This can be attributed
to the difference in viral genotypes as the previous study
was made on genotype 1 [19]. Additionally, it also
showed no relation in none-advanced liver disease pa-
tients though, larger sample size is recommended to as-
sure our findings.
Regarding the second ISG examined SNP (rs1127309)
is a synonymous variant in ADAR gene, our study on
the whole populatin and after excluding advanced fibro-
sis grades patients found no association between ADAR
gene polymorphism and Peg-IFN and RBV treatment
outcomes. This disagrees with the previous study made
by Welzel, et al. [20]. And could be explained by the dif-
ference in the percent of genetic variation (presence of
T allele) accounted by the selected ADAR SNP. Where
in European American the presence of T allele is about
(50 %) and our Caucasian population is (66 %). Add-
itionally, the previous study was a Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C) trial
unlike our study which includes insignificant number of
cirrhotic patients.
In agreement with other studies suggested adding AFP
to the list of predictive factors for treatment response in
CHC G4 [40, 41]. Our results showed that increased
AFP serum levels are an independent factor of thera-
peutic failure. This may be explained by intense hepatic
progenitor cells expression in NR compared to SVR.
Hepatic progenitor cells arise in the periportal region of
the liver and may be responsible for liver regeneration
and they express high levels of AFP. Quite interestingly,
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hepatic progenitor cells expression is associated with re-
sponse to treatment, being higher in NR compared with
responders. This may postulate the factor explaining the
association of AFP with therapeutic failure [42, 43]. Our
results showed that serum AFP levels is not a predictor
of SVR in none-advanced liver disease and this also
agreed with a study made on G4 [41].
In alignment with other published studies [30, 44] our
research didn’t find association between cholesterol
levels, insulin levels and HOMA-IR with antiviral re-
sponse this may be probably explained by the absence of
diabetes among our patients. On the other hand it was
found that baseline lower viral load is a direct predictor
to SVR rates as proved previously [45].
Finally we confirmed for the first time that vitamin D
related genes (VDR rs2228570 and CYP2R1 rs10741657)
polymorphism are completely independent of each other,
may be usefully combined to enhance the predictive
ability for treatment response. Where combing these
two genes with IL28B rs12979860 C/C genotype increase
the probability of SVR from 80 % to reach 100 %. Com-
pared with patients carrying the IL28B rs12979860 C/C
genotype and who carry at least one A allele of VDR
rs2228570 and CYP2R1 rs10741657, the none A allele
carriers identified patients showed a lower probability of
SVR attainment. Furthermore, carrying at least one T al-
lele of IL28B along with none A allele carrier of VDR
rs2228570 and CYP2R1 rs10741657 gene showed the
lowest probability of attaining the same viral endpoint.
Yet increased the probability of SVR in IL28B C/T + T/T
from 27 % to reach 50 %. Advanced fibrosis was proven
previously to be a main factor for Peg-IFN and RBV
treatment failure [45]. Thus more practically our study
interestingly found that only serum levels of 25-OH vita-
min D, VDR rs2228570 A/A genotype together with
IL28B rs12979860 C/C genotype were the only predic-
tors of SVR in none-F4 CHC patients. Moreover, we
proved that the presence of VDR rs2228570 A/A geno-
type and IL28B rs12979860 C/C genotype increased SVR
rates from 82 % reaching 100 % and more importantly
combining VDR rs2228570 A/A genotype and IL28B C/
T + T/T genotypes dramatically increase SVR from 29 %
to reach 80 % which impressively increase treatment
success prediction. Although promising yet larger sam-
ple size is required to assure our findings.
However in accordance with these data presented vita-
min D related genes play an integrative role with IL2B
gene in achieving SVR rates in CHC G4 patients.
Conclusions
In conclusion two polymorphic sites in VDR gene and
CYP2R1 gene were found to increase the sensitivity and
accuracy of IL28B gene in predicting SVR rates for Peg-
IFN and RBV therapy in CHC patients G4. The
association of these polymorphisms with the response rate
is independent from other well-known predictors of re-
sponse at baseline that were included in the multivariate
analysis as potentially confounding factors. The use of
these new genes could facilitate the treatment decision
and individualize the therapeutic regimens by totally as-
suring patient’s cure under low cost standard basic dual
therapy.
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